GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Elsevier BV ; 2018
    In:  Revue Francophone des Laboratoires Vol. 2018, No. 498 ( 2018-01), p. 49-59
    In: Revue Francophone des Laboratoires, Elsevier BV, Vol. 2018, No. 498 ( 2018-01), p. 49-59
    Type of Medium: Online Resource
    ISSN: 1773-035X
    Language: French
    Publisher: Elsevier BV
    Publication Date: 2018
    detail.hit.zdb_id: 2222772-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Nature Communications, Springer Science and Business Media LLC, Vol. 14, No. 1 ( 2023-06-13)
    Abstract: Two tumor (Classical/Basal) and stroma (Inactive/active) subtypes of Pancreatic adenocarcinoma (PDAC) with prognostic and theragnostic implications have been described. These molecular subtypes were defined by RNAseq, a costly technique sensitive to sample quality and cellularity, not used in routine practice. To allow rapid PDAC molecular subtyping and study PDAC heterogeneity, we develop PACpAInt, a multi-step deep learning model. PACpAInt is trained on a multicentric cohort ( n  = 202) and validated on 4 independent cohorts including biopsies (surgical cohorts n  = 148; 97; 126 / biopsy cohort n  = 25), all with transcriptomic data ( n  = 598) to predict tumor tissue, tumor cells from stroma, and their transcriptomic molecular subtypes, either at the whole slide or tile level (112 µm squares). PACpAInt correctly predicts tumor subtypes at the whole slide level on surgical and biopsies specimens and independently predicts survival. PACpAInt highlights the presence of a minor aggressive Basal contingent that negatively impacts survival in 39% of RNA-defined classical cases. Tile-level analysis (  〉  6 millions) redefines PDAC microheterogeneity showing codependencies in the distribution of tumor and stroma subtypes, and demonstrates that, in addition to the Classical and Basal tumors, there are Hybrid tumors that combine the latter subtypes, and Intermediate tumors that may represent a transition state during PDAC evolution.
    Type of Medium: Online Resource
    ISSN: 2041-1723
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2023
    detail.hit.zdb_id: 2553671-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 82, No. 12_Supplement ( 2022-06-15), p. 472-472
    Abstract: Introduction: Pancreatic adenocarcinoma (PAC) is highly heterogeneous, resulting in overall ineffectiveness of most anti-tumor treatments. Two tumor subtypes (Classical and Basal) and two stromal subtypes (“active” and “inactive”) have been described. The Basal and the active stroma have worse prognosis. These subtypes could also be predictive of the response to different chemotherapies. To date, molecular subtype classification or phenotype quantification can only be defined by RNAseq, a complex technique sensitive to the quantity and quality of samples, requiring a timescale limiting its routine application. We propose a deep learning approach (PACpAInt) to predict molecular subtypes in PAC on routine histological slides. Patients and Methods: 424 digitalized HES slides of 202 resected PAC from 3 centers with clinical and transcriptomic data were used as training cohort. 3 validation cohorts were used (i) 250 resected PAC from a 4th center including 97 cases with an exact HES/RNAseq spatial match and all tumor slides digitalized (n = 891); (ii) 126 resected PAC from the TCGA (HES + RNAseq); (iii) 25 liver biopsies from metastatic PAC (HES + RNAseq). A multi-step deep learning model was developed to recognize tumor tissue, tumor from stroma cells, and then predicts their transcriptomic molecular subtypes, either at the level of an entire slide, or at the tile level (squares of 112 μm) allowing to study intratumor heterogeneity. Results: PACpAInt correctly predicted the tumor subtype at the whole slide level (AUC = 0.86 and 0.81 in 2 validation cohorts) and improved for samples with unambiguous molecular subtype (AUC = 0.91 and 0.88) confirming the limit of a binary approach. Similar results were obtained on liver biopsies (AUC = 0.85 and 0.92 on unambiguous cases). PACpAInt independently predicted progression-free and overall survival (PFS HR=1.37 [1.16 - 1.62] and OS HR=1.27 [1.08 - 1.49] ). Analysis of all tumor slides from 77 Classical cases showed that 39% were heterogeneous with a Basal contingent. These cases had shorter PFS (15 vs. 47 months, p= 0.001) and OS (31 vs. 64 months, p= 5e-5).The analysis of intratumoral heterogeneity using PACpAInt predicted the molecular subtype of tumor and stroma cells of each tile within a slide ( & gt; 6 million tiles analyzed). 61% of cases had a main subtype either Classical (42%) or Basal (19%). 39% of the cases were ambiguous could be considered either hybrid (10%) with coexistence of Basal and Classical cells, or intermediate (29%) corresponding to homogeneous tumors but of intermediate differentiation. This classification had a strong prognostic impact (OS: 45.1 vs 33.0 vs 23.4 vs 13.6 months, resp. Classical, intermediate, hybrid, Basal; p & lt;e-12). Conclusion: This study provides the first PAC subtyping tool widely usable in clinical practice, opening the possibility of molecular classification useful for routine care and clinical trials. Citation Format: Charlie Saillard, Flore Delecourt, Benoit Schmauch, Olivier Moindrot, Magali Svrcek, Armelle Bardier-Dupas, Jean Francois Emile, Mira Ayadi, Vinciane Rebours, Louis De Mestier, Pascal Hammel, Cindy Neuzillet, Jean Baptiste Bachet, Juan Iovanna, Nelson Dusetti, Yuna Blum, Magali Richard, Yasmina Kermezli, Valerie Paradis, Mikhail Zaslavskiy, Pierre Courtiol, Aurelie Kamoun, Remy Nicolle, Jerome Cros. PACpAInt: A deep learning approach to identify molecular subtypes of pancreatic adenocarcinoma on histology slides [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 472.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2022
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 39, No. 15_suppl ( 2021-05-20), p. 4141-4141
    Abstract: 4141 Background: Pancreatic adenocarcinoma (PAC) is predicted to be the second cause of death by cancer in 2030 and its prognosis has seen little improvement in the last decades. PAC is a very heterogeneous tumor with preeminent stroma and multiple histological aspects. Omic studies confirmed its molecular heterogeneity, possibly one of the main factors explaining the failure of most clinical trials. Two and three transcriptomic subtypes of tumor cells and stroma respectively, were described with major prognostic and predictive implications. The tumor subtypes, Basal-like and Classical, have been shown by several groups to be predictive of the response to first line chemotherapy. As of today, these subtypes can only be defined by RNA profiling which is limited by the quantity and quality of the samples (formalin fixation and low cellularity) as well as by the analytical delay that may restrict its application in routine care. In addition, tumors may harbor a mixture of several subtypes limiting their interpretation using bulk transcriptomic approaches and thereby their clinical use. Here, we propose a multistep approach using deep learning models to predict tumor components and their molecular subtypes on routine histological preparations. Methods: 728 whole-slide digitized histological slides corresponding to 350 consecutive resected PAC from four centers with clinical and transcriptomic data were assembled and used as a discovery set. PAC from TCGA (n = 134) was used as a validation set. Tumor regions from slides of the discovery set were annotated to train a multistep deep learning model that first recognizes tumor tissue and then predicts tumor and stroma cells molecular subtypes assessed by the published PurIST algorithm. Results: The tumor detection model was very efficient (AUC = 0.98 in the TCGA validation cohort). In the discovery set, the Basal-like/Classical classification performance of the model by cross validation was 0.79 (AUC) and reached 0.86 when restricted to samples with a high-confidence RNA-defined molecular subtype.Subtypes defined by the model were independently associated with overall survival in multivariate analysis (HR = 2.56 [1.87 - 3.49], pval 〈 0.001), and association was higher relatively to PurIST RNA subtypes (HR = 1.60 [1.17 - 2.19] pval 〈 0.001). In the validation cohort, the model had an overall AUC of 0.82, and 0.89 in the subset of “subtype-pure” tumors. In addition to demonstrating the value of histology-based deep learning models for tumor subtyping in PAC, these results also show the limit of molecular-based subtyping in highly heterogeneous samples. Conclusions: This study provides the first PAC subtyping tool usable worldwide in clinical practice, finally opening the possibility of patient molecular stratification in routine care and clinical trials.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2021
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...